Neurocrine Biosciences (BSP:N1BI34) FCF Margin % : 24.10% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Neurocrine Biosciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Neurocrine Biosciences's Free Cash Flow for the three months ended in Sep. 2024 was R$830 Mil. Neurocrine Biosciences's Revenue for the three months ended in Sep. 2024 was R$3,445 Mil. Therefore, Neurocrine Biosciences's FCF Margin % for the quarter that ended in Sep. 2024 was 24.10%.

As of today, Neurocrine Biosciences's current FCF Yield % is 3.37%.

The historical rank and industry rank for Neurocrine Biosciences's FCF Margin % or its related term are showing as below:

BSP:N1BI34' s FCF Margin % Range Over the Past 10 Years
Min: -735.26 Med: 16.98 Max: 21.69
Current: 19.53

During the past 13 years, the highest FCF Margin % of Neurocrine Biosciences was 21.69%. The lowest was -735.26%. And the median was 16.98%.

BSP:N1BI34's FCF Margin % is ranked better than
89.94% of 994 companies
in the Drug Manufacturers industry
Industry Median: 0.9 vs BSP:N1BI34: 19.53

Neurocrine Biosciences FCF Margin % Historical Data

The historical data trend for Neurocrine Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences FCF Margin % Chart

Neurocrine Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

16.79

20.81

20.56

21.69

19.16

Neurocrine Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															40.98	22.92	23.11	8.98	24.10

Competitive Comparison of Neurocrine Biosciences's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurocrine Biosciences's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's FCF Margin % falls into.

Neurocrine Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Neurocrine Biosciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	1771.768	/	9246.413
	=	19.16 %

Neurocrine Biosciences's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	830.116	/	3445.065
	=	24.10 %

Neurocrine Biosciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (BSP:N1BI34) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

NBIX:USA 0K6R:UK NB3:Germany NB3:Germany

Address

12780 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences Headlines

No Headlines